WALTHAM, MA — Eigner, a leading
developer of precision product lifecycle management (PLM) solutions, today announced that it has received a $17 million investment from Ampersand Ventures. The funds will be used to continue the company’s product development and customer support initiatives, and to expand the company’s sales, marketing and business development programs as it begins an aggressive strategy to enter
new world markets.
SUNNYVALE & MENLO PARK, CA — Epicor Inc., a medical device company leading the development of new technologies to treat patients with atrial fibrillation, announced today that it closed a Series C $20 million private round of financing. The Sprout Group, a venture capital affiliate of Credit Suisse First Boston, led the institutional placement, with additional participation by InterWest Partners, Coral Partners and Johnson & Johnson Development Corp.
LOS ANGELES — Arcturus Capital today announced the launch of the Arcturus Capital Core Technology Fund to capitalize on fundamental and disruptive technologies developed in collaboration with HRL Laboratories, The Jet Propulsion Laboratory (JPL) and other world-class research labs.
The Los Angeles based venture capital firm unveiled its partnership with technology development company X-Laboratories, through which Arcturus will have the exclusive opportunity to finance operating companies addressing large commercial markets and based on technologies developed by top scientists from HRL Laboratories, JPL, and other state-of-the-art research facilities.
PLEASANTON, CA — Xign Corp., the leading provider of financial supply chain applications and services, today announced that it has closed $20 million in Series B funding. Leading this second round of funding was Financial Technology Ventures (FTVentures), which manages more than $600 million for some of the largest financial institutions in the world. Other investors participating in Series B funding included Matrix Partners, Charles River Ventures, RDM Corporation, and Charles R. Schwab.
PALO ALTO, CA — 3i, a leading international venture capital company which last week shut down most of its European offices and laid off 17% of its workforce, today announced that J. Sanford (Sandy) Miller has joined 3i’s Palo Alto office as Managing Director. Miller will oversee 3i’s later-stage technology investments in the United States.
A co-founder of Thomas Weisel Partners, Miller brings significant experience and expertise to 3i, particularly in the areas of technology and healthcare entrepreneurial growth companies. With more than 25 years of investment related experience, he has financed over 250 technology/growth companies including Siebel, Solectron and Yahoo!
PALO ALTO, CA — Apax Partners Inc. announced today that Alexander Wong, Ph.D. has joined the firm as a Partner in the IT/Telecom group, where he will specialize in semiconductor, optical and emerging technology investments.
Dr. Wong was formerly a Managing Director of Technology Investments at Intel Capital, where he led a technology group responsible for investment and mergers & acquisitions activities in semiconductor technologies, micro-electro-mechanical systems (MEMS), nanotechnologies, and display technologies.
ARMONK, NY — Op40 Inc. (formerly known as
International Interactive Commerce Ltd.), today announced that it has
received $15 million in financing led by Baker Capital. This brings Op40’s
total financing to $22 million. The company is driving the transformation
of the Internet from a content distribution medium to a business application
platform. Op40’s software improves the performance of Web applications and
enables businesses to optimize their IT investments by increasing the
deployment options for distributing content, data and applications over
existing Internet infrastructures. The company also announced today the
appointment of John Andrews as CEO, an important addition to Op40’s
world-class management team. Andrews was formerly chairman, CEO and founder
of e-MedSoft.com and previously served as chief information officer at CSX
MACCABIM, ISRAEL — Glycominds Ltd. today announced the successful completion of a $7.1 Million private placement. Glycominds is a biotechnology company pioneering new glycomics technologies for analyzing the interactions between complex carbohydrates (glycans) and proteins. Glycominds’ technologies have created a breakthrough in elucidating these interactions and are expected to help identify many new drug targets as well as dramatically improve early-stage drug development.
The investment round was led by Israel’s Millennium Materials Technologies Fund L.P. and included the participation of other venture capital funds as well as Germany’s Schott Glas, the high-tech manufacturer of special glass and other special materials.
For yesterday’s Wire, click here